- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex refractory fistulising Crohn disease
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 598KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 138KB)
Ustekinumab – November 2024
Ustekinumab; Injection 45 mg in 0.5 mL single use pre-filled syringe, Injection 90 mg in 1 mL single use pre-filled syringe, Solution for I.V. infusion 130 mg in 26 mL; Steqeyma®
Last updated
30 May 2025
